• Home
  • NEW DAY MEDICINE
  • 9 (83) 2025
  • 61 -9 (83) 2025 - Rakhimova Sh.K., Butabayeva M.M. - INTEGRATED EVALUATION OF NEUROIMMUNE MARKERS AND NEUROLOGICAL STATUS IN POST-COVID ADOLESCENTS FOR PERSONALIZED REHABILITATION STRATEGIES

61 -9 (83) 2025 - Rakhimova Sh.K., Butabayeva M.M. - INTEGRATED EVALUATION OF NEUROIMMUNE MARKERS AND NEUROLOGICAL STATUS IN POST-COVID ADOLESCENTS FOR PERSONALIZED REHABILITATION STRATEGIES

INTEGRATED EVALUATION OF NEUROIMMUNE MARKERS AND NEUROLOGICAL STATUS IN POST-COVID ADOLESCENTS FOR PERSONALIZED REHABILITATION STRATEGIES

Rakhimova Sh.K. - Andijan state medical institute

Butabayeva M.M. - Andijan state medical institute

Azizova R.B. - Andijan state medical institute

Tashmatov A.K. - Andijan state medical institute

Resume

Background: Post-COVID syndrome (PCS) in adolescents is increasingly recognized as a multidisciplinary challenge with neurological, immunological, and psychosocial implications. Neuroimmune biomarkers such as glial fibrillary acidic protein (GFAP) and monocyte chemoattractant protein-1 (MCP-1) provide insight into astroglial injury and persistent neuroinflammation, which may underlie long-term neurological dysfunction. Despite growing awareness of PCS, evidence on pediatric populations remains limited, and data integrating neuroimmune profiling with rehabilitation outcomes are scarce. Objective: To conduct a comprehensive assessment of neuroimmune markers and neurological status in adolescents during the post-COVID period and to evaluate their role in guiding personalized rehabilitation strategies. Methods: A total of 65 adolescents (10–17 years) with documented COVID-19 history and 20 healthy controls were recruited at Andijan Medical Institute. Neurological evaluation included structured clinical examination, the Asthenic State Scale (ASS), and Vein’s Autonomic Dysfunction Scale. Electroencephalography (EEG) was performed with quantitative spectral analysis. Neuroimmune markers (GFAP, MCP-1) were measured using enzyme-linked immunosorbent assay (ELISA). Rehabilitation interventions included standard therapy, non-pharmacological rehabilitation, and supplementation with Kretamin (a complex of vitamins, amino acids, and herbal extracts). Results: Adolescents with PCS showed significantly higher GFAP and MCP-1 levels compared to controls (p < 0.05). EEG revealed increased theta activity and reduced alpha power, correlating with higher fatigue and autonomic dysfunction scores. The Kretamin group demonstrated superior therapeutic response: 60% high effectiveness vs. 30% in the non-pharmacological group. Neuroimmune markers correlated with severity of clinical manifestations, supporting their prognostic utility. Conclusion: Neuroimmune biomarkers GFAP and MCP-1 are associated with neurological manifestations of PCS in adolescents. Their integration into clinical assessment may inform personalized rehabilitation strategies. Supplementation with Kretamin enhanced recovery beyond standard rehabilitation, highlighting the potential of biomarker-guided therapeutic approaches. Larger multicenter trials are needed to validate these findings and establish evidence-based pediatric rehabilitation protocols.

Keywords: COVID-19; Adolescents; Post-COVID syndrome; Neuroimmune biomarkers; GFAP; MCP-1; Electroencephalography; Neurology; Rehabilitation; Personalized medicine

First page

372

Last page

381

For citation:Rakhimova Sh.K., Butabayeva M.M., Azizova R.B., Tashmatov A.K. - INTEGRATED EVALUATION OF NEUROIMMUNE MARKERS AND NEUROLOGICAL STATUS IN POST-COVID ADOLESCENTS FOR PERSONALIZED REHABILITATION STRATEGIES//New Day in Medicine 9(83)2025 372-381 https://newdayworldmedicine.com/en/new_day_medicine/9-83-2025

List of References

  1. Buonsenso, D., Munblit, D., De Rose, C., Sinatti, D., Ricchiuto, A., Carfi, A., Valentini, P. (2022). Long COVID in children: The hidden impact on pediatric health. The Lancet Child Adolescent Health, 2022;6(1);8-10. https://doi.org/10.1016/S2352-4642(21)00350-7
  2. Kanberg N., Ashton N. J., Andersson L. M., Yilmaz A., Lindh M., Nilsson S., ... Gisslén M. (2021). Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology, 2021;95(12):1754-1759. https://doi.org/10.1212/WNL.0000000000010111
  3. Kas A., Soret M., Pyatigoskaya N., Habert M.O., Hesters A., Le Guennec L., ... Guedj E. (2022). Long COVID: Involvement of brainstem and cerebellum? Journal of Nuclear Medicine, 2022;63(1):33–39. https://doi.org/10.2967/jnumed.121.262262
  4. Mahad D. J., Ransohoff R. M. (2003). The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Seminars in Immunology, 2003;15(1):23-32. https://doi.org/10.1016/S1044-5323(02)00125-2
  5. Osmanov I. M., Spiridonova E., Bobkova P., Gamirova A., Shikhaleva A., Andreeva M., ... Lazareva I. (2021). Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. European Respiratory Journal, 2021;59(2):210-341. https://doi.org/10.1183/13993003.01341-2021
  6. Korolyova N.V., Kolesnikov S.I., Vorobyov S.V. (2013). Phenomenological atlas of clinical electroencephalography. Irkutsk: [Publisher]. 2013; 102 pp.
  7. Abdel-Mannan O., Eyre M., Lobel U., Bamford A., Eltze C., Hameed B., et al. (2020). Neurologic and radiographic findings associated with COVID-19 infection in children. JAMA Neurology, 2020;77(11):1440-1445. https://doi.org/10.1001/jamaneurol.2020.2687
  8. Cavalcanti A., Islabão A., Magalhães C., Veloso S., Lopes M., do Prado R., Aquilante B., et al. (2022). Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): A Brazilian cohort. Advances in Rheumatology, 2022;62(1):6. https://doi.org/10.1186/s42358-022-00237-4
  9. Chang W. T., Toh H. S., Liao C. T., Yu W. L. (2021). Cardiac involvement of COVID-19: A comprehensive review. American Journal of the Medical Sciences, 2021;361(1):14-22. https://doi.org/10.1016/j.amjms.2020.10.002
  10. Petrova N. N., Morozov P. V., Markin A. V., Bekker R. A., Bykov Yu. V. (2020). The COVID-19 pandemic: Current challenges and the latest data on rational psychopharmacotherapy in patients with SARS-CoV-2. Psychiatry and Psychopharmacotherapy, 2020;6:8-24.
  11. Becker J. H., Lin J. J., Doernberg M., Stone K., et al. (2021). Assessment of cognitive function in patients after COVID-19 infection. JAMA Network Open, 2021;4(10):213-645. https://doi.org/10.1001/jamanetworkopen.2021.30645
  12. Kazarin A.P., Selikhanova V.M. (2021). Post-COVID depression: A literature review. Science and Health, 2021;23(3):16-23.
  13. Zaichik A. Sh., Poletaev A. B., Churilov L. P. (2013). Recognition of “self” and interaction with “self” as the main form of adaptive immune system activity. Medicine, 2013;1:6-27.

    file

    download